Q2 EPS Estimates for Legend Biotech Reduced by HC Wainwright

Legend Biotech Co. (NASDAQ:LEGN) – Equities research analysts at HC Wainwright cut their Q2 2025 earnings per share estimates for shares of Legend Biotech in a research report issued to clients and investors on Wednesday, November 13th. HC Wainwright analyst M. Kapoor now anticipates that the company will post earnings of $0.24 per share for the quarter, down from their previous forecast of $0.28. HC Wainwright has a “Buy” rating and a $73.00 price objective on the stock. The consensus estimate for Legend Biotech’s current full-year earnings is ($1.48) per share. HC Wainwright also issued estimates for Legend Biotech’s Q4 2025 earnings at $0.12 EPS.

A number of other equities research analysts also recently commented on the stock. Redburn Atlantic initiated coverage on shares of Legend Biotech in a research report on Tuesday, October 8th. They issued a “buy” rating and a $86.00 price objective on the stock. Royal Bank of Canada reiterated an “outperform” rating and issued a $86.00 price objective on shares of Legend Biotech in a report on Tuesday, October 29th. Finally, Scotiabank boosted their target price on Legend Biotech from $70.00 to $76.00 and gave the stock a “sector outperform” rating in a research note on Monday, August 12th. Thirteen research analysts have rated the stock with a buy rating, According to data from MarketBeat, Legend Biotech currently has a consensus rating of “Buy” and an average target price of $81.46.

Legend Biotech Stock Down 2.1 %

LEGN stock opened at $39.35 on Thursday. The company’s 50 day moving average price is $46.49 and its 200 day moving average price is $48.34. The firm has a market capitalization of $7.17 billion, a price-to-earnings ratio of -41.42 and a beta of 0.11. Legend Biotech has a fifty-two week low of $38.60 and a fifty-two week high of $70.13. The company has a debt-to-equity ratio of 0.25, a quick ratio of 4.78 and a current ratio of 4.84.

Legend Biotech (NASDAQ:LEGN) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.34) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.22. The business had revenue of $160.20 million for the quarter, compared to analyst estimates of $143.91 million. Legend Biotech had a negative return on equity of 29.22% and a negative net margin of 66.92%. The company’s revenue was up 66.9% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.17) earnings per share.

Institutional Trading of Legend Biotech

Institutional investors and hedge funds have recently bought and sold shares of the business. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of Legend Biotech by 61.8% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 50,268 shares of the company’s stock worth $2,450,000 after buying an additional 19,198 shares during the last quarter. Bridgewater Associates LP increased its stake in Legend Biotech by 0.3% in the 3rd quarter. Bridgewater Associates LP now owns 165,975 shares of the company’s stock valued at $8,088,000 after buying an additional 516 shares during the period. Quantbot Technologies LP purchased a new position in Legend Biotech during the 3rd quarter worth $148,000. FMR LLC lifted its stake in shares of Legend Biotech by 4.0% in the 3rd quarter. FMR LLC now owns 18,330,219 shares of the company’s stock worth $893,232,000 after acquiring an additional 708,620 shares during the period. Finally, Dynamic Technology Lab Private Ltd purchased a new stake in shares of Legend Biotech in the third quarter valued at about $306,000. Hedge funds and other institutional investors own 70.89% of the company’s stock.

About Legend Biotech

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM).